Introduction. Oxymatrine is a natural quinazine alkaloid extracted from Sophora flavescens and has many medicinal values. Oxymatrine showed protective effects, viral inhibition and effects against lung cancer. Hypothesis/Gap Statement. Individuals with lung cancer exhibit heightened vulnerability to COVID-19 infection due to compromised immune function. In conjunction with COVID-19, it is hypothesized that oxymatrine may exert potent pharmacological effects on lung cancer patients. Aim. The objective of this study was to assess the pharmacological mechanisms and targets of oxymatrine in relation to COVID-19 lung cancer. Methodology. Utilizing network pharmacology analysis, a selection of 2628 genes were identified as co-targets for both COVID-19 and lung cancer. Subsequently, a clinicopathological analysis was conducted by integrating RNA-Seq and clinical data obtained from the TCGA-LUAD lung cancer dataset, which was acquired from the official TCGA website. The identification of pharmacological targets for oxymatrine was accomplished through the utilization of various databases including Pharm mapper, SWISS Target prediction, and STITCH. These identified targets were further investigated for protein-protein interaction (PPI) using STRING, as well as for gene ontology (GO) and KEGG pathways. Results. The effects of oxymatrine on COVID-19-induced lung cancer were mediated by immune regulation, cytoprotection, antiviral, and anti-inflammatory activities, immune regulation, and control of related signalling pathways, including the formation of the neutrophil extracellular trap, phagosome, Toll-like receptor signalling pathway, apoptosis, proteoglycans in cancer, extracellular matrix disassembly, and proteolysis involved in cellular protein catabolism. Furthermore, important substances and genes like ALB, MMP3, MMP1, and TLR4 may affect how oxymatrine suppresses lung cancer/COVID-19 development. Conclusion. To treat COVID-19 or lung cancer paired with COVID-19, oxymatrine may improve the therapeutic efficacy of current clinical antiviral medicines and immunotherapy.

中文翻译：

---

基于网络药理学探索氧化苦参碱与COVID-19与肺癌的交叉基因作为潜在治疗靶点

介绍。氧化苦参碱是从苦参中提取的天然奎嗪生物碱，具有多种药用价值。氧化苦参碱具有保护作用、病毒抑制作用和抗肺癌作用。假设/差距陈述。由于免疫功能受损，肺癌患者更容易感染 COVID-19。与 COVID-19 结合，推测氧化苦参碱可能对肺癌患者发挥有效的药理作用。目的。本研究的目的是评估氧化苦参碱与 COVID-19 肺癌相关的药理学机制和靶点。方法。利用网络药理学分析，选定的 2628 个基因被确定为 COVID-19 和肺癌的共同靶标。随后，通过整合RNA-Seq和从TCGA官方网站获得的TCGA-LUAD肺癌数据集获得的临床数据进行临床病理学分析。氧化苦参碱药理靶标的鉴定是通过利用各种数据库完成的，包括 Pharm mapper、SWISS Target Prediction 和 STITCH。使用 STRING 进一步研究这些确定的靶标的蛋白质-蛋白质相互作用 (PPI)，以及基因本体 (GO) 和 KEGG 通路。结果。氧化苦参碱对 COVID-19 诱导的肺癌的作用是通过免疫调节、细胞保护、抗病毒和抗炎活性、免疫调节和相关信号通路的控制来介导的，包括中性粒细胞胞外陷阱、吞噬体、Toll 的形成类受体信号通路、细胞凋亡、癌症中的蛋白聚糖、细胞外基质分解以及细胞蛋白质分解代谢中涉及的蛋白水解。此外，ALB、MMP3、MMP1 和 TLR4 等重要物质和基因可能会影响氧化苦参碱抑制肺癌/COVID-19 发展的方式。结论。对于治疗COVID-19或与COVID-19合并的肺癌，氧化苦参碱可能会提高目前临床抗病毒药物和免疫疗法的治疗效果。